Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Foundation Grant

University of British Columbia

$5,635,004.00

Fibrosis as a progenitor disease: novel therapeutic opportunities

FY 2017-18

Summary
Centrain tissues in our bodies, such as skeletal muscle, are very capable of regenerating and going back to functioning perfectly in response to acute damage. However, when such damage is repeated over and over again, as it happens in chronic disease, regeneration no longer works and fibrosis develops. The goal of my research is to understand what goes wrong in chronic damage, and to use this new knowledge to formulate new therapies to prevent fibrosis and enhance regeneration. Fibrosis is the most common complication of chronic disease, which is on the rise in Canada, and is estimated to be involved in 45% of deaths. As no efficacious therapy for fibrosis exists, a new approach has blockbuster potential and would greatly benefit the health of Canadians, the health care budget and the Canadian economy at large
Program
Foundation Grant
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
369394
Name
Rossi Fabio M
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
Foundation Grant
Projecttitle
Fibrosis as a progenitor disease: novel therapeutic opportunities
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$5,635,004
Cihrequipment2
$0
Programname2
Foundation Grant
Keyworddelim
Fibrosis; Intercellular Signalling Networks; Mesenchymal Progenitors; Tissue Regeneration
Abstract
Centrain tissues in our bodies, such as skeletal muscle, are very capable of regenerating and going back to functioning perfectly in response to acute damage. However, when such damage is repeated over and over again, as it happens in chronic disease, regeneration no longer works and fibrosis develops. The goal of my research is to understand what goes wrong in chronic damage, and to use this new knowledge to formulate new therapies to prevent fibrosis and enhance regeneration. Fibrosis is the most common complication of chronic disease, which is on the rise in Canada, and is estimated to be involved in 45% of deaths. As no efficacious therapy for fibrosis exists, a new approach has blockbuster potential and would greatly benefit the health of Canadians, the health care budget and the Canadian economy at large
Competitiondate
201709
Approvedterm2
7 yrs 0 mth
Pinamesdelim
Rossi, Fabio M
Approvedterm
7 ans 0 mois
Cihrcontribution2
~ $5,635,004~ $0~